This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2008;299(19):2263-2264.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Findings from a new study challenge current guidelines for the treatment of stage 2 hypertension.

The study's findings, presented at the American College of Cardiology's annual scientific session here in March, found that high-risk patients with hypertension who received a calcium-channel blocker (CCB) combined with an angiotensin-converting enzyme (ACE) inhibitor experienced 20% less cardiovascular morbidity and mortality than did patients taking an ACE inhibitor plus a thiazidetype diuretic. The difference was so significant that the study was stopped early.

A low-cost combination therapy that includes a calcium-channel blocker and an angiotensin-converting enzyme inhibitor may provide the best control of stage 2 hypertension while reducing risk for cardiovascular events. (Photo credit: Robert Bremec/iStockphoto.com)

Current guidelines from the Seventh Report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf) call for treating patients with stage 1 hypertension . . . [Full Text of this Article]

UNCONTROLLED HYPERTENSION



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?